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Intravenous immunoglobulins (IVIg) are therapeutic preparations of normal human IgG
that have been used for more than 20 years for substitutive therapy in patients with
primary antibody deficiencies. Recent studies pointed out the need to obtain normal
residual levels of IgG (i.e. 8 g/L) in order to reduce the number and severity of bacterial
infections in these patients. The IVIg are also prescribed for the substitutive therapy of
secondary immunodeficiencies such as chronic lymphoid leukemia and multiple mye-
loma with hypogammaglobulinemia and severe and/or recurrent infections, and human
immunodeficiency virus (HIV)-infected children with recurrent bacterial infections
before the era of highly active antiretroviral agents. However, in the latter situation,
no recent study has evaluated IVIg therapy in acquired immunodeficiency syndrome
(AIDS) children receiving highly active antiretroviral agents (HAART), and the use of
IVIg must probably be restricted to the currently rare clinical situation in Western Europe
of children with AIDS who develop recurrent infections despite the administration of
HAART and prophylactic cotrimoxazole. IVIg have also been reported to prevent
infections, interstitial pneumonia and graft-vs. host disease during the first 90 days
post-transplant in allogeneic bone-marrow transplant recipients. However, this result
was not confirmed by two recent studies and IVIg therapy should probably only be
proposed for a subgroup of bone-marrow allografted patients such as those with
hypogammaglobulinemia and sepsis. With the exception of erythrovirus B19 infection
with erythroblastopenia, no clear benefit of IVIg therapy has been reported for the
curative management of other infectious diseases.
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I N T R A V E N O U S I M M U N O G L O B U L I N
S U B S T I T U T I V E T H E R A P Y
Intravenous immunoglobulins (IVIg) are thera-
peutic preparations of normal human IgG that
are obtained from a pool of more than 1000 healthy
blood donors and contain a wide spectrum of
antibacterial and antiviral specificities [1]. IVIg,
which were used for the first time in 1980 as a
substitutive therapy in patients, mostly children,
with primary antibody deficiencies, reduce the
incidence and severity of acute infectious compli-
cations such as upper and lower respiratory tract
and meningeal bacterial infections as compared to
immunoglobulins (Igs) administered by the intra-
muscular route [2,3]. Consequently, other thera-
peutic indications of IVIg in substitutive treatment
have been evaluated. In chronic lymphoid leuke-
mia (CLL) [4] and multiple myeloma [5] with
hypogammaglobulinemia and severe and/or
recurrent infections related to encapsulated bac-
teria, a protective effect of IVIg has been demon-
strated, particularly for the prevention of upper
and lower respiratory tract infections. However, it
should be noted that no beneficial effect was
obtained for the prevention of viral and fungal
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infections. IVIg had also been reported to prevent
recurrent bacterial infections in HIV-infected chil-
dren before the era of highly active antiretroviral
agents (HAART) [6]. And IVIg have also been
reported to prevent the occurrence of Gram-nega-
tive septicemia and local infections, interstitial
pneumonia and graft- vs. host disease (GVHD)
during the first 90 days post-transplant in allo-
geneic bone-marrow transplant recipients [7,8].
Based on recent literature, we provide new insights
into the use of IVIg either for prophylaxis or
curative treatment of infectious diseases. Utiliza-
tion of IVIg as an immunomodulating agent in
autoimmune and systemic inflammatory diseases
has been detailed in a number of review articles
[9,10] and will not be considered here.
U N A N S W E R E D Q U E S T I O N S F O R
P R I M A R Y I M M U N O D E F I C I E N C I E S
Although IVIg can be utilised in a wide spectrum
of antibody deficiencies, many questions regard-
ing substitutive therapy remain unanswered.
Thus, IVIg therapy in primary antibody deficien-
cies does not totally prevent the occurrence of
infectious diseases. Indeed, bronchiectasis and
chronic sinusitis are often encountered, as well
as other infections such as enteroviral menin-
goencephalitis in X-linked agammaglobulinemia
patients [11]. In adults, 17% of common variable
immunodeficiency (CVID) patients present with
bronchectasis at the time of diagnosis [12]. In a
double-blind, cross-over study, Eijkhout et al.
showed that a high-dose of IVIg (adults,
600 mg/kg every 4 weeks; children, 800 mg/kg
every 4 weeks) significantly reduced the number
and duration of infections compared to the stan-
dard dose (adults, 300 mg/kg of body weight
every 4 weeks; children, 400 mg/kg every
4 weeks), while the serum levels of IgG increased
significantly from 6.5 g/L during low-dose ther-
apy to 9.4 g/L during high-dose therapy [13].
Thus, in the light of results of recent studies, we
might suggest that the residual level of 8 g/L of
serum IgG should be achieved in order to prevent
the occurrence of bacterial infections. However,
there was no significant difference in this study
between the two groups for the occurence of Cam-
pylobacter and Giardia lamblia infections [13]. In
addition, despite this optimal level of IgG and
adequate antibiotics, some patients still develop
bowel infections or chronic sinusitis and bronch-
ectasis. Finally, other factors that remain to be
determined could also contribute to the suscept-
ibility to infections in these patients. Interestingly,
some CVID patients with low mannose-binding
lectin alleles present an increased risk of infection
compared to others [14].
U N A N S W E R E D Q U E S T I O N S
F O R S E C O N D A R Y
I M M U N O D E F I C I E N C I E S
Although no data are available yet regarding four
dosages of IVIg over 300 mg/kg of body weight
every 4 weeks in substitutive therapy of CLL and
multiple myeloma, by analogy to what has been
recently demonstrated in the substitutive therapy
of primary immunodeficiencies, could be assumed
that increasing the residual serum level of IgG to
8 g/L in these patients might also lower the inci-
dence and severity of bacterial infections. This
must, however, be demonstrated in prospective
studies. In other secondary immune deficiencies,
certain questions remain unanswered and will be
briefly discussed below.
HIV infection
Since evidence was obtained that IVIg decreased
the number of serious bacterial infections in HIV-
infected children before the availability of zidovu-
dine [6], the therapeutic management of children
with HIV infection has improved. In a randomised
double-blind trial in children who had AIDS or an
AIDS-related complex and received zidovudine,
comparing either IVIg or placebo, the IVIg
decreased the risk of serious bacterial infections.
However, this benefit was apparent only in chil-
dren who did not receive trimethoprim-sulfa-
methoxazole as a prophylaxis of opportunistic
infections [15]. Unfortunately, no recent study
has evaluated the IVIg therapy in children with
AIDS who are receiving HAART. Thus, the use of
IVIg must probably be restricted to the currently
rare clinical situation in Western Europe of chil-
dren with AIDS who develop recurrent infections
despite the administration of HAART and pro-
phylactic cotrimoxazole. Although some evidence
has been obtained that prophylactic IVIg treatment
in HIV-infected adults decreases the frequency of
serious infections before the HAART era, these
data are controversial, because they were not cor-
rected for concommitant trimethoprim-sulfa-
methoxazole prophylactic treatment and almost
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25% of the patients were excluded from the study
[16]. Thus, at the present time the prophylactic use
of IVIg to prevent the occurrence of recurrent
bacterial infections in HIV-infected adults cannot
be recommended.
Allogeneic bone-marrow transplantation
Since IVIg was approved in the 1990s for use in
allogeneic bone-marrow transplant recipients for
the prevention of GVHD and infections during
the first 90 days post-transplant [8], other studies
evaluated the efficacy of lower doses of IVIg.
In a multicenter, randomised, double-blind trial,
100 mg/kg, 250 mg/kg or 500 mg/kg doses of
IVIg were evaluated weekly for 90 days and then
monthly until 1 year after grafting. No significant
difference was found in terms of frequency of
acute or chronic GVHD, infection and interstitial
pneumonia, types of infection, relapse of hema-
tological malignancy or survival, except for more
frequent minor secondary effects in the group
receiving high-dose therapy [17]. Another recent
prospective randomised study compared placebo
and 50, 250 and 500 mg/kg/w doses of IVIg given
from day 7 to day 100 in 200 allogeneic sibling
stem-cell transplant (SCT) patients. Despite a sig-
nificant beneficial effect of a high-dose IVIg in
preventing acute GVHD ¼ 2, there was no overall
benefit of IVIg over the placebo after allogeneic
geno-identical SCT. By contrast, the significantly
deleterious effect of IVIg on the occurrence of
fatal veno-occlusive disease may counterbalance
their benefit for GVHD prevention [18]. On the
basis of these results, and in light of the elevated
cost of IVIg therapy, we wonder whether IVIg ther-
apy remains beneficial for all bone-marrow allo-
grafted patients or should only be proposed for a
subgroup of patients such as those with hypogam-
maglobulinemia and sepsis. There is no proven
benefit from IVIg in prophylaxis of infections in
patients undergoing bone-marrow autograft [19].
Numerous studies have reported the use of anti-
CMV Ig preparations in patients undergoing bone-
marrow allograft. Eight years ago, a meta-analysis
reported a beneficial effect of anti-CMV Ig pre-
parations in such patients, with a decreased occur-
rence of CMV lung infections and other symptoms
associated to CMV infection, and a diminution of
GVHD reactions [20]. These results were, how-
ever, not confirmed in more recent studies which,
on the contrary, did not show any difference in
incidence of CMV infection incidence in patients
receiving standard IVIg (400 mg/kg/week) vs.
IgG-CMV enriched (100 mg/kg/week) [21]. Thus,
we do not recommend the use of IgG-CMV
enriched preparations in this indication.
Solid-organ transplantation
Considerable effort has been made in the pro-
phylactic and curative treatment of CMV
infection in patients undergoing solid-organ trans-
plantation. In a retrospective analysis renal-
transplant patients treated with ganciclovir during
the initial hospital stay followed by 3 months of
acyclovir therapy and a historical control group
that received IVIg and acyclovir were compared.
Among all patients studied, ganciclovir did not
differ from IVIg in preventing CMV infection but
was considerably less expensive. A lower inci-
dence of CMV infection was observed in patients
treated with ganciclovir as compared to IVIg in a
subgroup in which the recipient was CMV sero-
negative and the donor was CMV seropositive
[22]. Considering recent progress in the prophy-
lactic antiviral strategy, such as the use of valacy-
clovir in kidney-transplant patients [23], we think
that IVIg should not be considered in this context.
In heart- and kidney-transplant recipients, IgG–
CMV-enriched preparations failed to demonstrate
a beneficial effect in a prospective study [24], and
their use in the prophylaxis of CMV infection
remains controversial [25].
Other secondary immunodeficiencies
IVIg are also utilised for the post-exposure pro-
phylaxis of immunodeficient patients and preg-
nant women who have been in contact with a
patient harboring chickenpox or zoster infection
in the preceding 72 h [26]. Many studies have been
conducted to evaluate the beneficial effect of IVIg
in the prophylactic treatment of infections in pre-
term and/or low-birth-weight infants. The results
are difficult to interpret, particularly owing to the
different schemes utilised in the different studies
[27]. In a prospective, randomised, placebo-con-
trolled study including 2400 preterm infants, no
beneficial effect of IVIg was demonstrated in terms
of short- and long-term prevention of infections,
duration of hospitalization or mortality [28]. Thus,
no evidence has been obtained yet that IVIg
could prevent infections in preterm and/or
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low-birth-weight infants [28]. There is also no
demonstration for the beneficial effect of IVIg in
the prophylaxis of severe sepsis in postoperative
patients [1]. Finally, there is no available data
providing evidence for the efficacy of IVIg in the
prevention of infections in patients with connec-
tive tissue or autoimmune diseases such as sys-
temic lupus erythematosus.
I V I G I N T H E C U R A T I V E T R E A T M E N T
O F I N F E C T I O N S
Therapeutic indications of IVIg in the curative
treatment of infections are limited. Erythroblasto-
penia owing to erythrovirus B19 infection,
whether related or not to HIV infection is the only
recognised indication of IVIg as a curative treat-
ment in the field of infectious diseases [29,30].
Other indications of IVIg for suspected or proven
sepsis are still being evaluated. Only four studies
evaluated the therapeutic effect of IVIg in the
curative treatment of sepsis in preterm infants
[31–34]. Despite the small number of patients
enrolled, two randomized, double-blind studies
provided evidence for the increased survival
in IVIg-treated infants [33,34]. However, recent
meta-analysis of the literature of IVIg treatment
for suspected or subsequently proven infection in
neonates did not indicate a statistically significant
reduction of mortality [35]. In adults, although
recent recommendations advocate that IVIG sig-
nificantly reduce mortality and can be used as an
adjuvant treatment for sepsis and septic shock [36],
this point remains debatable. IgG–CMV-enriched
preparations are also utilized in the curative treat-
ment of severe CMV infection in patients under-
going solid-organ transplantation. Although no
benefit of IgG–CMV enriched preparations is
observed when they are administered as a sole
treatment, a beneficial effect has been reported in
combination with ganciclovir in the treatment of
CMV pneumopathy [37,38]. IgG–CMV-enriched
preparations are also utilized in the treatment of
ganciclovir-resistant CMV infections.
Anecdoctal observations of the efficacy of IVIg
in the treatment of streptococcal toxic shock syn-
drome [39], infection-associated macrophage acti-
vation syndrome [40] and Clostridium difficile
infection [41] have also been reported. However,
in our opinion, based on the existing literature, the
use of IVIg cannot be recommended in the latter
indications.
I V I G T R E A T M E N T O F I M M U N E
T H R O M B O C Y T O P E N I C P U R P U R A
( I T P ) R E L A T E D T O V I R A L I N F E C T I O N
In addition to replacement therapy in patients with
primary or secondary antibody deficiencies, IVIg
were shown 20 years ago to increase the number
of platelets in patients with immune thrombocyto-
penic purpura (ITP) [42]. Since then, it has been
shown that IVIg is effective in the treatment of ITP
secondary to HIV infection [43] or other viral infec-
tions such as the Epstein–Barr virus (EBV).
M E T H O D S O F A D M I N I S T R A T I O N
O F I V I G
The IVIg-substitutive therapy consists of intrave-
nous infusions of 600 mg/kg every 4 weeks in
adults, and 800 mg/kg every 4 weeks in children,
adapted to the residual serum IgG level. Because
long-term IVIg infusion can be complicated by
poor venous access, systemic-adverse reactions,
and the need for frequent hospital admission,
rapid subcutaneous Ig infusion in children with
primary immunodeficiencies could be an effective,
convenient and well-tolerated alternative to intra-
venous treatment [44]. In a recent randomized
cross-over trial comparing subcutaneous and IVIg
replacement therapy in primary immunodeficien-
cies, no significant difference in the clinical efficacy
or adverse reaction rates was observed between
the Ig-replacement therapy given subcutaneously
or intravenously [45]. However, because of an
increased risk of adverse events, patients with
significant thrombocytopenia, high levels of anti-
IgA antibodies, or a past history of severe adverse
reactions to a blood product within the last 2 years
did not receive IVIg-subcutaneous replacement
therapy at home [45].
Because IVIg are obtained from plasma of a
pool of healthy blood donors, there is a potential
risk of transmission of infectious agents through
IVIg infusion. However, since the last series of
transmission of HCV infection in 1994, no case
of transmission of any infectious disease with
IVIg has recently been reported. Nanofiltration
of IVIg preparations will certainly decrease the
risk of transmission of an infectious agent.
C O N C L U S I O N
In conclusion, IVIg are indicated for substitutive
therapy in patients with antibody deficiencies.
Recentstudiespointedouttheneedtoobtainnormal
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residual levels of IgG (i.e. 8 g/L) in primary anti-
body deficiencies. Considering secondary antibody
deficiencies, a clearbenefit has been documentedfor
the prevention of bacterial infections in plateau
phasemultiplemyelomaandCLL,althoughnoclear
residual level of IgG has been validated in this
setting.WiththeexceptionoferythrovirusB19infec-
tion with erythroblastopenia, no clear benefit of IVIg
therapy has been reported for the curative manage-
ment of other infectious diseases.
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